All News

Delegates at the recent FlyPharma Conference pick out collaboration as their main goal for the coming year.

Preliminary findings from pilot study validate use of wearable technologies to collect data and manage clinical trials more effectively and efficiently.

Demonstrated significant improvements in disease signs and symptoms at 24 weeks among patients with active psoriatic arthritis who had prior inadequate response or intolerance to TNF inhibitors.

Investment will focus on new innovations in therapeutics for neurodegeneration, antibiotic resistance, cancer and respiratory diseases.

Sandoz believes its combination product will offer asthma and COPD patients same safety and efficacy as reference medicine.

Extends EMEA sales team with addition of two new regional sales leaders in DACH and Southern Europe regions.

Enables labs around the world to generate more useful information from complex proteins, antibodies, polypeptides and polysaccharides.

Company adds fifth building in Southern California.

Company's CFO leaves to join another biopharma company.

Investment allows company to increase its capacity to handle E&L projects for applications including container testing, medical device evaluation and testing equipment used in pharmaceutical production.

Study successfully met its primary endpoint and Bekinda 24 mg was shown to be effective, safe and well tolerated in patients with acute gastroenteritis and gastritis.

Currently there are no approved topical NSAIDs indicated for the treatment of migraine.

Aker BioMarine, a biotech innovator and Antarctic krill harvesting company dedicated to improving human and planetary health, has been named as Norway’s most innovative company by Innovasjonsmagasinet, Norway’s leading innovation magazine. Innovasjonsm...

New results presented at AHS.

Argus improves the quality and timeliness of safety case processing and reporting, and reduces operational risks for both clinical trial and post-marketed pharmacovigilance data.

Espranor represents the first major advance available in opioid substitution therapy for 10 years.

Application "addresses a critical information gap that has existed for decades between pharmaceutical companies, pharmacists and patients."

Injection abuse of reformulated Opana ER has been associated with a serious outbreak of HIV and hepatit.is C

As of today, all major brands of nasal decongestant topical sprays in the US come with Aptar Pharma’s child-resistant feature.

Investments will strengthen the excipients, polymers, drug formulation and manufacturing, and medical device contract manufacturing capabilities throughout the company's global facilities.

Highly flexible system for a broad range of processes.

Selling iNova part of Valeant's efforts to simplify and strengthen its balance sheet.

Collaboration to focus on a potential new class of treatments for metabolic disorders.

BIOCORP signs an industrialization contract with Virbac for the manufacturing of an innovative administration and closure system compatible with vials.

The Committee will review analytical, pharmacokinetic and clinical data from studies involving ABP 215, including results from a Phase III study in patients with NSCLC.

Using the solution stable enzyme can eliminate unnecessary waste and cost.

NOVA-EM is Novatek's solution dedicated to managing all aspects of an automated environmental monitoring program.

Removes burden of validating software updates for Life Sciences Cloud customers.

Phase I/II study to evaluate the combination of Opdivo (nivolumab) and Opdivo +Yervoy (ipilimumab) regimen with Mekinist (trametinib) in patients with colorectal cancer.

Expanding market for biosimilars and biobetters is anticipated to pronounce the demand for contract development and manufacturing support.

Lonza has successfully completed the acquisition of PharmaCell, a cell and gene contract manufacturer in Europe with employees in Maastricht and Geleen (NL). In 2016, PharmaCell had sales of EUR 11 million.

Continuous manufacturing process will enable improved quality control and cGMP compliance, while reducing energy consumption, waste and raw material.

The new technical service laboratory is the company's 20th across the world.

Combination of nivolumab plus ipilimumab can fundamentally change survival expectations.

QbD studies in upstream processing more rapidly performed.

Collaboration will use real-world patient data and cognitive computing with aim of improving outcomes in advanced breast cancer.

Gen-Plus is a small medium-sized, privately owned company.

Its aim is to discover innovations for contract partners. We 

design formulation and technology concepts for the 

pharmaceutical industry. This includ...

Robust data from Phase III studies demonstrated positive impact on motor milestone achievement; increased survival in infants with SMA.

Porvair Glass Vial Deep-well plates are precisely manufactured to ensure complete compatibility with automated equipment.

NICE has recommended immunotherapy drug nivolumab for the treatment of adult patients with classical Hodgkin lymphoma.

Agreement provides access to Orkambi for people who have two copies of the F508del mutation and expands access to Kalydeco for all eligible patients.

Finding may lead to therapies that prevent pituitary tumor recurrence.

Pharmaceutical companies should play a larger role in patient support programs.

Deal adds the first plasma-derived treatment to Hima's product offering.

Biosimilar infliximab alone could potentially save the NHS £89 million.

Microdermics has successfully demonstrated the initial safety of its microneedle system, and is planning Phase I human clinical trials for vaccine and therapeutic delivery, to be initiated in 2017.

Flysyn is the first antibody from the company's pipeline to be tested in humans.

The expansion is part of an ongoing strategic campaign to invest in small molecule API manufacturing across the company's global network of facilities.

Acquisition of Jaco enables Sanner to operate as a system supplier.

Under the terms of this new agreement, PCT will provide GMP-compliant manufacturing services for Orchard’s lead product, OTL-101, an autologous ex-vivo gene therapy for the treatment of ADA-SCID.

TheraT mediated alarmin release crucial for active immunization in cancer immunotherapy.

Shabbir Mostafa to join the CDMO as Director, Business Management, with responsibility for driving sales of Recipharm’s manufacturing services.

Recall due to out of sequence tablets and missing expiry/lot information.

Marken today announced it has launched a new hybrid logistics service which leverages the UPS global transportation network, and has already received customer commitments for the new service. The hybrid service enables Marken to utilize the UPS network...

Application is based on results from the Phase I/II CheckMate -040 trial.

Amongst highest levels of immune responses ever demonstrated in an HIV vaccine human study.

New webinar hosted by Xtalks focuses on extracting the most value from data assets.

First initiative is to eliminate visible particles from parenteral products,

Unipharma has applied state-of-the-art technology to traditional products and made the first ever Mono-Dose/Unit-Dose OTC line of products which will forever change the way people consume medications. No more confusions, no more charts, no more scie...

The addition of this antibody targeting tau will complement Merck’s portfolio of candidates being investigated for the treatment of Alzheimer's disease.

Industry and regulators combine to run afternoon congress on the implications of regulatory changes.

First clinical study using a patent protected minocycline API and formulation developed by Hovione.

Aplidin is PharmaMar's second most advanced anticancer drug currently under development for the treatment of multiple myeloma and angioimmunoblastic T-cell lymphoma.

Separate subgroup analysis demonstrates long-term efficacy of Ofev in slowing disease progression is maintained for up to 96 weeks in IPF patients who require dose adjustments to manage adverse events.

Strengthens pipeline with lead candidate TNT009 in cold agglutinin disease, a rare and chronic autoimmune hemolytic anemia with no approved therapies.

EirGen have commenced construction of a state of the art R&D facility in the Business and technology Park, Cork road, Waterford (Opposite the Whitfield clinic). The facility will be construction complete in Q2 2018 with a phased start up leading to...

New rotogravure printing machine and a new cutting machine in operation since the end of 2014.

Kevzara is now available to US patients.

New analyses from the FLAME study suggest dual bronchodilator Ultibro Breezhaler provides similar or better efficacy versus steroid-containing therapies, regardless of blood eosinophil counts.

In all analyses, people experiencing uncontrolled asthma symptoms saw improvements in their breathing by adding Spiriva Respimat to an ICS or combination ICS/LABA.

Sixth FDA approval for Actemra since its US launch in 2010,

Patheon provides entry into the attractive, high-growth CDMO market.

It is the first and only biopharmaceutical manufacturing site established by a multinational active pharmaceutical company in China.

Product adds to the company's non-injectables portfolio in the US.

Proposal extends application to the treatment of children and adolescents with chronic phase Philadelphia-chromosome positive chronic myelogenous leukemia and to the powder for oral suspension.

Phase III-ready program complements Biogen’s ongoing development efforts in stroke.

New medium designed for hematopoietic cell culture for cell-based therapies.

Accelerates development timelines with faster, easier selection and scale up of clones.

Research used to produce a global ranking of countries’ pharma reputation, market growth potential, innovation and competitiveness.

Expansion part of global investment in testing capabilities.

Unique tool will allow massive quantities of cell culture data to be collected during upstream processing QbD studies.

Certification covers the manufacture and packaging of hard and soft gel capsules, liquids for external use, semi-solids such as ointments and film coated tablets.

Exclusive worldwide license for FC-Cubes

Friulchem S.p.A., a chemical-pharmaceutical company active in human and veterinary fields, has received an US Patent (US Patent 14/11856) covering own solid form called “pseudo-crystalline” solid form, derived from Rifamycin O.

New company name reflects diverse market opportunities.

The e-Lockout device being the first and only fully integrated electronic nasal drug delivery device to be approved by a US or European regulatory authority.

Increases site’s reactor capacity by 30%.

SGS has expanded storage capacity at its laboratory in Mississauga, Canada, for the effective stability testing of new drug substances and products for full regulatory compliance.

Catalent Biologics will use its proprietary GPEx technology to produce different protein variants for Therachon,

Allows customers to achieve a more optimal output than they would using conventional batch or fed-batch processes.

Many companies currently unprepared because they lack the internal resources to devote to serialization.

New pivotal results for Perjeta and Alecensa demonstrating improvement over standards of care.

NIH-funded clinical trial shows use of either drug improved vision and had few side effects.

Company believes low likelihood of approval this year.

FDA approves Keytruda as first-line combination therapy with pemetrexed and carboplatin for patients with metastatic nonsquamous non-small cell lung cancer (NSCLC) irrespective of PD-L1 expression.

Discontinuation due to the vaccine supplier’s (GSK) decision to discontinue global production.

Thermo Fisher Scientific helps research service providers and their customers optimize protein identification and quantitation.

Status marks the company as the first multi-site excipient supplier to achieve global EXCiPACT accreditation across its production facilities.

Kit increases efficiency of residual protein A ligand detection.

IMvigor211 failed to meet its primary endpoint of overall survival (OS) compared with chemotherapy.

Board helps to steer the overall development of CPHI events and content.

Goldfinch Bio’s researchers select StarDrop to guide successful drug discovery.

Xermelo is a first-in-class orally administered therapy for the treatment of carcinoid syndrome diarrhea.

Highly precise dosing of smallest amounts of API.

When compared with current hard sublingual tablets, the novel formulation dissolved quickly with no increased safety concerns and no demonstrable difference in efficacy.

Inside Rx, a new initiative from Express Scripts, partners with GoodRx, drug manufacturers and drug stores to save Americans an average of 34% at 40,000 pharmacies

European Commission approves Keytruda for patients with relapsed or refractory classical Hodgkin lymphoma who failed ASCT and BV or who are transplant-ineligible and have failed BV.

A key focus on Cherwell’s Stand A49 will be the microbiology requirements for pharmacy aseptic manufacturing, preparation and dispensing.

New ProSolus commercial team will provide potential partners throughout the pharmaceutical industry direct access to the state-of-the-art research, development, and manufacturing capabilities.

Strain represents one of the common current circulating strains of influenza of a pandemic origin.

Company will be responsible for the GMP preparation and filling of AB569 into glass vials.

This chemistry testing offer complements the company’s existing range of off-the-shelf biological assays for biosimilar products, providing a complete solution from one contract partner.

SGS announced the successful completion of a Phase I clinical trial of a new strain of influenza virus in healthy volunteers.

Combined expertise is likely to have a significant impact in reducing the costs and complexity of ophthalmic clinical trials.

With lower rates of obesity, the researchers say rates of heart disease, diabetes, and other diseases that tend to increase with age, including cancer and Alzheimer’s disease, could fall as well.

Library claimed to offer "the most efficient route to therapeutic antibody lead identification".

Expansion doubles manufacturing capacity and includes the introduction of new facilities.

Imfinzi is the cornerstone in an extensive immuno-oncology program across multiple cancer types and stages of disease.

Trial designed to evaluate the safety and efficacy of CTP-543 after 12 months of dosing with the primary efficacy analysis at week 24.